Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Acepodia wins FDA clearance for dual-payload GPC3 ADC in liver cancer

5 September 2026 · By · Wire by Fusion42

Published

5 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 5 September 2026 · Fusion42 review

Acepodia has received FDA clearance to start Phase I trials for ACE723, a dual-payload ADC targeting GPC3 in unresectable or metastatic hepatocellular carcinoma. This is the first clinical program from their Antibody-Dual-Drugs Conjugation platform, addressing an unmet need in liver cancer post-immunotherapy failure.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a narrow window to leap into post-immunotherapy liver cancer treatments as FDA has opened clinical testing for dual-payload ADCs. This clearance rewires the path for biotech founders targeting resistant solid tumours with novel conjugate strategies.

◆ Coverage

1 source · 5 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-clearanceliver-canceradcdual-payloadclinical-trials